Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to -$3.3 million.

  • KalVista Pharmaceuticals' Cash from Investing Activities rose 9736.26% to -$3.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$43.7 million, marking a year-over-year increase of 4844.25%. This contributed to the annual value of $91.0 million for FY2025, which is 20744.23% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$3.3 million for Q2 2025, which was up 9736.26% from $48.7 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Cash from Investing Activities registered a high of $48.7 million during Q4 2024, and its lowest value of -$126.2 million during Q2 2024.
  • For the 3-year period, KalVista Pharmaceuticals' Cash from Investing Activities averaged around -$316000.0, with its median value being $19.6 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 7044.75% in 2024, then surged by 9736.26% in 2025.
  • Quarter analysis of 3 years shows KalVista Pharmaceuticals' Cash from Investing Activities stood at $28.6 million in 2023, then soared by 70.45% to $48.7 million in 2024, then crashed by 106.84% to -$3.3 million in 2025.
  • Its Cash from Investing Activities was -$3.3 million in Q2 2025, compared to $48.7 million in Q4 2024 and $37.2 million in Q3 2024.